Vaxcyte (PCVX) Net Cash Flow (2019 - 2026)

Vaxcyte (PCVX) has 8 years of Net Cash Flow data on file, last reported at $87.5 million in Q1 2026.

• Net Cash Flow for Q1 2026 came in at $87.5 million, up 307.47% year-over-year; the trailing twelve-month figure through Mar 2026 was -$86.5 million (up 66.74% YoY), and the FY2025 annual result was -$216.2 million, down 2109.6% from the prior year.
• Net Cash Flow grew to $87.5 million in Q1 2026 per PCVX's latest filing, from -$107.3 million in the prior quarter.
• Over five years, Net Cash Flow peaked at $555.5 million in Q4 2022 and troughed at -$663.7 million in Q4 2024.
• A 5-year average of $11.6 million and a median of $13.3 million in 2023 frame the typical range for Net Cash Flow.
• The sharpest annual moves came in 2023 and 2024: Net Cash Flow plunged 441.57% in 2023, then soared 3945.4% in 2024.
• A 5-year view of Net Cash Flow shows it stood at $555.5 million in 2022, then slumped by 125.2% to -$140.0 million in 2023, then sank by 374.04% to -$663.7 million in 2024, then surged by 83.83% to -$107.3 million in 2025, then soared by 181.59% to $87.5 million in 2026.
• Business Quant data shows PCVX's Net Cash Flow at $87.5 million in Q1 2026, -$107.3 million in Q4 2025, and -$25.8 million in Q3 2025.